Sean Bohen, Olema
November 19, 2020 08:14 AM EST
Financing

Sean Bo­hen hauls in a mul­ti­mil­lion-dol­lar wind­fall as his new­ly adopt­ed biotech bags a $209M-plus IPO

John Carroll

Editor & Founder

Sean Bo­hen’s IPO for Ole­ma On­col­o­gy priced at $19 a share overnight, go­ing over the top of the range and giv­ing him an ini­tial mul­ti­mil­lion …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

Ad­vanz Phar­ma faces re­vo­ca­tion of Eu­ro­pean au­tho­riza­tion for liv­er dis­ease drug Ocali­va

Bris­tol My­ers sues the fed­er­al gov­ern­ment over 340B, fol­low­ing oth­er drug­mak­ers

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

A service from the Financial Times